Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Verrica's Compensation Committee granted David Zawitz, Verrica's new Chief Operating Officer, a nonqualified stock option to purchase 950,000 shares of its common stock under the Company's Inducement Plan, effective December 9, 2024. The stock option was granted as a material inducement to Mr. Zawitz's employment with Verrica in accordance with Nasdaq Listing Rule 5635(c)(4).
宾夕法尼亚州西切斯特，2024年12月9日（环球新闻）——Verrica制药公司（"Verrica"或"公司"）（纳斯达克：VRCA），一家开发需要医疗干预的皮肤病药物的皮肤科学治疗公司，今天宣布Verrica的薪酬委员会授予David Zawitz，Verrica的新任首席运营官，一项非合格股票期权，允许他根据公司的引导计划购买950,000股普通股，生效日期为2024年12月9日。该股票期权是为了作为Zawitz先生加入Verrica的实质性诱因而授予的，符合纳斯达克上市规则5635(c)(4)。
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Verrica (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Verrica, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
引导计划仅用于向之前不是Verrica的员工或非员工董事的个人授予股权奖励（或在经过真正的非就业期后），作为这些个人加入Verrica工作的重要诱因，依据纳斯达克上市规则5635(c)(4)。
The option award will have an exercise price equal to the closing price of Verrica's common stock on December 9, 2024. The option award will vest and become exercisable as to 1/8th of the shares on the date that is six months following Mr. Zawitz's start date, and 1/48th of the shares each month thereafter on the same day of the month as the start date, subject to Mr. Zawitz's continuous service with Verrica on such vesting dates. The option award is subject to the terms and conditions of the Inducement Plan, and the terms and conditions of a stock option agreement covering the grant.
股票期权的行使价格等于2024年12月9日Verrica普通股的收盘价。股票期权将于Zawitz先生的开始控件日期后的六个月时自动生效，针对1/8的股份生效，此后每个月在与开始控件日期相同的日期对1/48的股份生效，前提是Zawitz先生在相关生效日期与Verrica保持持续服务。股票期权适用引导计划的条款和条件，以及覆盖该授予的股票期权协议的条款和条件。
About Verrica Pharmaceuticals Inc.
关于Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's product YCANTH (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit .
verrica制药是一家开发皮肤病医疗治疗药物的医疗公司。verrica的产品YCANTH (VP-102) (cantharidin)是美国 FDA 批准用于治疗两岁及以上的成人和儿童患者的首个商业化治疗选项，该产品适用于羊皮癣，一种高度传染性的病毒性皮肤感染，影响着美国大约600万人，主要是儿童。YCANTH (VP-102)还在研发中，用于治疗普通疣和外生殖器疣，这两种是医疗皮肤科领域最大的未满足需求之一。verrica还在开发其第二个基于cantharidin的产品候选VP-103，用于治疗足底疣。verrica还与Lytix Biopharma AS签订了全球许可协议，开发和销售VP-315 (以前称为LTX-315和VP-LTX-315)，用于非黑素瘤皮肤癌，包括基底细胞癌和鳞状细胞癌。请访问了解更多信息。
FOR MORE INFORMATION, PLEASE CONTACT:
欲获得更多信息，请联系:
Investors:
投资者：
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
凯文·加德纳
生命科学顾问
kgardner@lifesciadvisors.com
Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com
Chris Calabrese
生命科学顾问
ccalabrese@lifesciadvisors.com
